Contact Us
Geographic Atrophy Global Market Report 2025
Global Geographic Atrophy Market Report 2025
Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF
Purchase This Report

Geographic Atrophy Global Market Report 2025

By Drug Type (Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drugs), By Diagnosis ( Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)), By Route Of Administration (Intravitreal, Oral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Geographic Atrophy Market Overview

• Geographic Atrophy market size has reached to $1.86 billion in 2024

• Expected to grow to $3.47 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%

• Growth Driver: Rising Prevalence Of Age-Related Macular Degeneration Driving Geographic Atrophy Market Growth Due To Aging Population Trends

• Market Trend: Innovative Complement Inhibitor Therapy Advancing Treatment Options For Progressive Eye Disease

North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Geographic Atrophy Market?

Geographic atrophy is an eye condition that causes gradual vision loss due to damage in the retina. It is a severe form of age-related macular degeneration (AMD) that leads to blind spots in central vision.

The main drug types of geographic atrophy are anti-vascular endothelial growth factor (VEGF) therapy, complement inhibitors, neuroprotective agents, others. Complement inhibitors are treatments that regulate an overactive immune response by blocking specific proteins involved in inflammation and cell damage. The various diagnosis includes fundus autofluorescence (FAF), optical coherence tomography angiography (OCT-A), multifocal electroretinography (mfERG). These are administered through various route of administration such as intravitreal, oral, other routes of administration and are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, others.

Geographic Atrophy Market Size and growth rate 2025 to 2029: Graph

What Is The Geographic Atrophy Market Size 2025 And Growth Rate?

The geographic atrophy market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.11 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to growing geriatric population, rising demand for effective treatment options, increasing prevalence of geographic atrophy, increasing health awareness, and rise in incidence of retinal diseases.

What Is The Geographic Atrophy Market Growth Forecast?

The geographic atrophy market size is expected to see rapid growth in the next few years. It will grow to $3.47 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to rising focus on research and development, increase in R&D investments, escalating usage of smartphones, increasing expenditure on healthcare, and increased investment in clinical trials. Major trends in the forecast period include advancements in gene therapy, advances in healthcare technology, development of new technologies, telemedicine adoption, and innovative and effective drugs.

The forecast of 13.2% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to complement inhibitor eye injections imported from Switzerland and Ireland, potentially accelerating vision loss in AMD patients and increasing ophthalmology treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Geographic Atrophy Market Segmented?

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drugs

2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)

3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegmentss:

1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: ranibizumab, Aflibercept, Bevacizumab

2) By Complement Inhibitors: Pegcetacoplan, Lfg316

3) By Neuroprotective Agents: Latanoprost, Brimonidine

4) By Other Drugs: Steroids, Retinoids, Combination Therapy

What Is Driving The Geographic Atrophy Market? Rising Prevalence Of Age-Related Macular Degeneration Driving Geographic Atrophy Market Growth Due To Aging Population Trends

Increasing prevalence of age-related macular degeneration is expected to propel the growth of the geographic atrophy market going forward. Age-related macular degeneration (AMD) is an eye condition that damages the central part of the retina of the older adults, making it difficult to see fine details. Aging population is the major reason for the prevalence of age-related macular degeneration, as more people are living longer, and the natural aging process causes gradual damage to the eyes, making them more vulnerable to the disease over time. Geographic atrophy treatment support age-related macular degeneration (AMD) patients by slowing the progression of retinal damage and preserving remaining vision. For instance, in January 2024, according to a report published by Medical News Today, a US-based digital media company, the global cases of age-related macular degeneration are expected to rise from 196 million to 288 million by 2040. Therefore, the increasing prevalence of age-related macular degeneration is driving the growth of the geographic atrophy industry.

Who Are The Major Players In The Global Geographic Atrophy Market?

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc., Boehringer Ingelheim, Astellas Pharma Inc., Biogen Inc., Ocugen Inc., Kodiak Sciences Inc., Apellis Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Voyager Therapeutics, Kriya Therapeutics, Stealth BioTherapeutics, Kiora Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Nanoscope Therapeutics, Graybug Vision, SparingVision, 4D Molecular Therapeutics, Clearside Biomedical, Gensight Biologics

What Are The Key Trends Of The Global Geographic Atrophy Market? Innovative Complement Inhibitor Therapy Advancing Treatment Options For Progressive Eye Disease

Major companies operating in the geographic atrophy market are focusing on innovative therapies such as complement inhibitor therapy to develop advanced treatments for geographic atrophy. Complement inhibitor therapy is a treatment that slows down an overactive immune response linked to certain diseases and helps protect healthy cells from damage and reduces disease progression. For instance, in February 2025, Astellas Pharma Inc., a Japan-based pharmaceutical company announced IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy approved by the Food and Drug Administration, a US-based government agency. This approval allows IZERVAY to be used without a limitation on the duration of dosing for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This decision provides greater flexibility for managing GA, offering longer-term treatment options for both patients and healthcare providers.

Need data on a specific region in this market?

What Are Latest Mergers And Acquisitions In The Geographic Atrophy Market? Bausch + Lomb Strengthens Ophthalmic Pipeline With Whitecap Biosciences Acquisition

In January 2025, Bausch + Lomb Corporation, a US-based pharmaceutical and medical device company that specializes in eye health products, acquired Whitecap Biosciences LLC for an undisclosed amount. With this acquisition, Bausch + Lomb aims to expand its portfolio of innovative eye health solutions by incorporating Whitecap Biosciences' expertise in advanced ocular therapeutics. Whitecap Biosciences LLC is a US-based pharmaceutical company that specializes in developing novel therapies for ophthalmic diseases including geographic atrophy.

What Is The Regional Outlook For The Global Geographic Atrophy Market?

North America was the largest region in the geographic atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Geographic Atrophy Market?

The geographic atrophy market consists of revenues earned by entities by providing gene therapies, and stem cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The geographic atrophy market also includes sales of artificial retinas, and medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Geographic Atrophy Industry?

The geographic atrophy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the geographic atrophy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Geographic Atrophy Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $2.11 billion
Revenue Forecast In 2034 $3.47 billion
Growth Rate CAGR of 13.2% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The geographic atrophy market covered in this report is segmented –
1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drugs
2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG)
3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels Subsegmentss:
1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab
2) By Complement Inhibitors: Pegcetacoplan, Lfg316
3) By Neuroprotective Agents: Latanoprost, Brimonidine
4) By Other Drugs: Steroids, Retinoids, Combination Therapy
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Regeneron Pharmaceuticals Inc., Boehringer Ingelheim, Astellas Pharma Inc., Biogen Inc., Ocugen Inc., Kodiak Sciences Inc., Apellis Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Voyager Therapeutics, Kriya Therapeutics, Stealth BioTherapeutics, Kiora Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Nanoscope Therapeutics, Graybug Vision, SparingVision, 4D Molecular Therapeutics, Clearside Biomedical, Gensight Biologics
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Geographic Atrophy Market Characteristics

3. Geographic Atrophy Market Trends And Strategies

4. Geographic Atrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Geographic Atrophy Growth Analysis And Strategic Analysis Framework

5.1. Global Geographic Atrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Geographic Atrophy Market Growth Rate Analysis

5.4. Global Geographic Atrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Geographic Atrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Geographic Atrophy Total Addressable Market (TAM)

6. Geographic Atrophy Market Segmentation

6.1. Global Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anti-Vascular Endothelial Growth Factor (VEGF) Therapy

Complement Inhibitors

Neuroprotective Agents

Other Drugs

6.2. Global Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Fundus Autofluorescence (FAF)

Optical Coherence Tomography Angiography (OCT-A)

Multifocal Electroretinography (mfERG)

6.3. Global Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravitreal

Oral

Other Routes Of Administration

6.4. Global Geographic Atrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other Distribution Channels

6.5. Global Geographic Atrophy Market, Sub-Segmentation Of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ranibizumab

Aflibercept

Bevacizumab

6.6. Global Geographic Atrophy Market, Sub-Segmentation Of Complement Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pegcetacoplan

Lfg316

6.7. Global Geographic Atrophy Market, Sub-Segmentation Of Neuroprotective Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Latanoprost

Brimonidine

6.8. Global Geographic Atrophy Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Steroids

Retinoids

Combination Therapy

7. Geographic Atrophy Market Regional And Country Analysis

7.1. Global Geographic Atrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Geographic Atrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Geographic Atrophy Market

8.1. Asia-Pacific Geographic Atrophy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Geographic Atrophy Market

9.1. China Geographic Atrophy Market Overview

9.2. China Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Geographic Atrophy Market

10.1. India Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Geographic Atrophy Market

11.1. Japan Geographic Atrophy Market Overview

11.2. Japan Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Geographic Atrophy Market

12.1. Australia Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Geographic Atrophy Market

13.1. Indonesia Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Geographic Atrophy Market

14.1. South Korea Geographic Atrophy Market Overview

14.2. South Korea Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Geographic Atrophy Market

15.1. Western Europe Geographic Atrophy Market Overview

15.2. Western Europe Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Geographic Atrophy Market

16.1. UK Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Geographic Atrophy Market

17.1. Germany Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Geographic Atrophy Market

18.1. France Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Geographic Atrophy Market

19.1. Italy Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Geographic Atrophy Market

20.1. Spain Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Geographic Atrophy Market

21.1. Eastern Europe Geographic Atrophy Market Overview

21.2. Eastern Europe Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Geographic Atrophy Market

22.1. Russia Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Geographic Atrophy Market

23.1. North America Geographic Atrophy Market Overview

23.2. North America Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Geographic Atrophy Market

24.1. USA Geographic Atrophy Market Overview

24.2. USA Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Geographic Atrophy Market

25.1. Canada Geographic Atrophy Market Overview

25.2. Canada Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Geographic Atrophy Market

26.1. South America Geographic Atrophy Market Overview

26.2. South America Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Geographic Atrophy Market

27.1. Brazil Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Geographic Atrophy Market

28.1. Middle East Geographic Atrophy Market Overview

28.2. Middle East Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Geographic Atrophy Market

29.1. Africa Geographic Atrophy Market Overview

29.2. Africa Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Geographic Atrophy Market Competitive Landscape And Company Profiles

30.1. Geographic Atrophy Market Competitive Landscape

30.2. Geographic Atrophy Market Company Profiles

30.2.1. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Boehringer Ingelheim Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Ocugen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Geographic Atrophy Market Other Major And Innovative Companies

31.1. Kodiak Sciences Inc.

31.2. Apellis Pharmaceuticals Inc.

31.3. NGM Biopharmaceuticals Inc.

31.4. Voyager Therapeutics

31.5. Kriya Therapeutics

31.6. Stealth BioTherapeutics

31.7. Kiora Pharmaceuticals

31.8. Iveric Bio

31.9. Alkeus Pharmaceuticals

31.10. Nanoscope Therapeutics

31.11. Graybug Vision

31.12. SparingVision

31.13. 4D Molecular Therapeutics

31.14. Clearside Biomedical

31.15. Gensight Biologics

32. Global Geographic Atrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Geographic Atrophy Market

34. Recent Developments In The Geographic Atrophy Market

35. Geographic Atrophy Market High Potential Countries, Segments and Strategies

35.1 Geographic Atrophy Market In 2029 - Countries Offering Most New Opportunities

35.2 Geographic Atrophy Market In 2029 - Segments Offering Most New Opportunities

35.3 Geographic Atrophy Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Geographic Atrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Geographic Atrophy Market, Sub-Segmentation Of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Geographic Atrophy Market, Sub-Segmentation Of Complement Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Geographic Atrophy Market, Sub-Segmentation Of Neuroprotective Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Geographic Atrophy Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Geographic Atrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Geographic Atrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Regeneron Pharmaceuticals Inc. Financial Performance
  • Table 80: Boehringer Ingelheim Financial Performance
  • Table 81: Astellas Pharma Inc. Financial Performance
  • Table 82: Biogen Inc. Financial Performance
  • Table 83: Ocugen Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Geographic Atrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Geographic Atrophy Market, Sub-Segmentation Of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Geographic Atrophy Market, Sub-Segmentation Of Complement Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Geographic Atrophy Market, Sub-Segmentation Of Neuroprotective Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Geographic Atrophy Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Geographic Atrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Geographic Atrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Regeneron Pharmaceuticals Inc. Financial Performance
  • Figure 80: Boehringer Ingelheim Financial Performance
  • Figure 81: Astellas Pharma Inc. Financial Performance
  • Figure 82: Biogen Inc. Financial Performance
  • Figure 83: Ocugen Inc. Financial Performance

Frequently Asked Questions

Geographic atrophy is an eye condition that causes gradual vision loss due to damage in the retina. It is a severe form of age-related macular degeneration (AMD) that leads to blind spots in central vision. For further insights on this market, request a sample here

The market major growth driver - Rising Prevalence Of Age-Related Macular Degeneration Driving Geographic Atrophy Market Growth Due To Aging Population Trends. For further insights on this market, request a sample here

The geographic atrophy market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.11 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to growing geriatric population, rising demand for effective treatment options, increasing prevalence of geographic atrophy, increasing health awareness, and rise in incidence of retinal diseases. The geographic atrophy market size is expected to see rapid growth in the next few years. It will grow to " $3.47 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to rising focus on research and development, increase in R&D investments, escalating usage of smartphones, increasing expenditure on healthcare, and increased investment in clinical trials. Major trends in the forecast period include advancements in gene therapy, advances in healthcare technology, development of new technologies, telemedicine adoption, and innovative and effective drugs. For further insights on this market, request a sample here

The geographic atrophymarket covered in this report is segmented –
1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Complement Inhibitors; Neuroprotective Agents; Other Drugs
2) By Diagnosis: Fundus Autofluorescence (FAF); Optical Coherence Tomography Angiography (OCT-A); Multifocal Electroretinography (mfERG)
3) By Route Of Administration: Intravitreal; Oral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab; Aflibercept; Bevacizumab
2) By Complement Inhibitors: Pegcetacoplan; Lfg316
3) By Neuroprotective Agents: Latanoprost; Brimonidine
4) By Other Drugs: Steroids; Retinoids; Combination Therapy For further insights on this market,
request a sample here

North America was the largest region in the geographic atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geographic atrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc., Boehringer Ingelheim, Astellas Pharma Inc., Biogen Inc., Ocugen Inc., Kodiak Sciences Inc., Apellis Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Voyager Therapeutics, Kriya Therapeutics, Stealth BioTherapeutics, Kiora Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Nanoscope Therapeutics, Graybug Vision, SparingVision, 4D Molecular Therapeutics, Clearside Biomedical, Gensight Biologics . For further insights on this market, request a sample here.

Major trends in this market include Innovative Complement Inhibitor Therapy Advancing Treatment Options For Progressive Eye Disease. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Back to top WhatsApp icon